Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.
about
Burden of costs associated with heparin-induced thrombocytopenia: is time to remove unfractionated heparin from the drug formularies in medical institutions?Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands.Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
P2860
Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cost-effectiveness analysis of ...... heparin/vitamin K antagonist.
@ast
Cost-effectiveness analysis of ...... heparin/vitamin K antagonist.
@en
type
label
Cost-effectiveness analysis of ...... heparin/vitamin K antagonist.
@ast
Cost-effectiveness analysis of ...... heparin/vitamin K antagonist.
@en
prefLabel
Cost-effectiveness analysis of ...... heparin/vitamin K antagonist.
@ast
Cost-effectiveness analysis of ...... heparin/vitamin K antagonist.
@en
P2093
P2860
P1433
P1476
Cost-effectiveness analysis of ...... heparin/vitamin K antagonist.
@en
P2093
Anne Guillermin
Dominic Muston
Euan McLeod
Julia Lowin
Luke Bamber
P2860
P2888
P356
10.1186/S12959-015-0051-3
P577
2015-06-11T00:00:00Z
P5875
P6179
1048263293